Von Willebrand disease secondary prevention: Difference between revisions

	Von Willebrand disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Von Willebrand disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Von Willebrand disease secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Von Willebrand disease secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Von Willebrand disease secondary prevention
on Von Willebrand disease secondary prevention
Von Willebrand disease secondary prevention in the news
Blogs on Von Willebrand disease secondary prevention
Directions to Hospitals Treating Von Willebrand disease
Risk calculators and risk factors for Von Willebrand disease secondary prevention

Latest revision as of 19:16, 31 August 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Prince Tano Djan, BSc, MBChB [2]

There are no known preventive measures for von Willebrand disease. In families with type 3 disease, genetic analysis may be useful for counseling.

There are no known preventive measures for von Willebrand disease.
In families with type 3 disease, genetic analysis may be useful for counseling.^[1]

↑ Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto Mdel M, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borràs N, Vidal F (2016). "Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm". Thromb. Haemost. 115 (1): 40–50. doi:10.1160/TH15-04-0282. PMID 26245874.

@@ Line 4: / Line 4: @@
 {{CMG}} {{PTD}}
 ==Overview==
-*There are no known preventive measures for von Willebrand disease.
+There are no known preventive measures for von Willebrand disease. In families with type 3 disease, genetic analysis may be useful for counseling.
-*In families with type 3 disease, genetic analysis may be useful for counseling.<ref name="pmid26245874">{{cite journal |vauthors=Batlle J, Pérez-Rodríguez A, Corrales I, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Toll T, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto Mdel M, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Borràs N, Vidal F |title=Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm |journal=Thromb. Haemost. |volume=115 |issue=1 |pages=40–50 |year=2016 |pmid=26245874 |doi=10.1160/TH15-04-0282 |url=}}</ref>
 ==Prevention==